Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies

[1]  C. Tse,et al.  ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. , 2008, Cancer research.

[2]  F Gambale,et al.  Inhibition of Bax channel-forming activity by Bcl-2. , 1997, Science.

[3]  K. Vousden,et al.  PUMA, a novel proapoptotic gene, is induced by p53. , 2001, Molecular cell.

[4]  P. Nowell,et al.  Pre-B-cell leukemia with a t(8; 14) and a t(14; 18) translocation is preceded by follicular lymphoma. , 1988, Oncogene.

[5]  G. Kroemer,et al.  Bcl-2 family members: Dual regulators of apoptosis and autophagy , 2008, Autophagy.

[6]  Mark A. Hall,et al.  Selection against PUMA Gene Expression in Myc-Driven B-Cell Lymphomagenesis , 2008, Molecular and Cellular Biology.

[7]  A. Strasser,et al.  Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic , 2006, Proceedings of the National Academy of Sciences.

[8]  A. Strasser,et al.  Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. , 2008, The Journal of clinical investigation.

[9]  R. Meadows,et al.  Structure of Bcl-xL-Bak Peptide Complex: Recognition Between Regulators of Apoptosis , 1997, Science.

[10]  R. Craig,et al.  MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[11]  T. Kuwana,et al.  BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. , 2005, Molecular cell.

[12]  D. Green,et al.  The Pathophysiology of Mitochondrial Cell Death , 2004, Science.

[13]  Dean P. Jones,et al.  Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked , 1997, Science.

[14]  J. M. Boyd,et al.  Bik, a novel death-inducing protein shares a distinct sequence motif with Bcl-2 family proteins and interacts with viral and cellular survival-promoting proteins. , 1995, Oncogene.

[15]  M. Butterworth,et al.  Evaluation and critical assessment of putative MCL-1 inhibitors , 2013, Cell Death and Differentiation.

[16]  G. Kroemer,et al.  Bcl-2 family members: dual regulators of apoptosis and autophagy. , 2008, Autophagy.

[17]  A. Strasser,et al.  The protein product of the oncogene bcl-2 is a component of the nuclear envelope, the endoplasmic reticulum, and the outer mitochondrial membrane. , 1994, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[18]  S. Matsuda,et al.  Bcl-xL overexpression in human hepatocellular carcinoma. , 2002, International journal of oncology.

[19]  D. Tenen,et al.  BIM Mediates EGFR Tyrosine Kinase Inhibitor-Induced Apoptosis in Lung Cancers with Oncogenic EGFR Mutations , 2007, PLoS medicine.

[20]  M. Cleary,et al.  Membrane topology of the Bcl-2 proto-oncogenic protein demonstrated in vitro. , 1990, The Journal of biological chemistry.

[21]  B. Li,et al.  MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R , 2013, Oncogene.

[22]  T. Inaba,et al.  Roles of Bim in Apoptosis of Normal and Bcr-Abl-Expressing Hematopoietic Progenitors , 2004, Molecular and Cellular Biology.

[23]  Xiaodong Wang,et al.  Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.

[24]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[25]  A. Strasser,et al.  Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics , 2007, PLoS medicine.

[26]  K. Franssila,et al.  BCL 2 Overexpression Associated With Chromosomal Amplification in Diffuse Large B-Cell Lymphoma , 1997 .

[27]  I. Weissman,et al.  Prevention of programmed cell death in Caenorhabditis elegans by human bcl-2. , 1992, Science.

[28]  S. Haldar,et al.  The bcl-2 gene encodes a novel G protein , 1989, Nature.

[29]  D. Green,et al.  How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? , 2008, Trends in cell biology.

[30]  Derek Y. Chiang,et al.  The landscape of somatic copy-number alteration across human cancers , 2010, Nature.

[31]  J. Opferman,et al.  Deletion of MCL-1 causes lethal cardiac failure and mitochondrial dysfunction. , 2013, Genes & development.

[32]  Christoph Borner,et al.  XIAP discriminates between type I and type II FAS-induced apoptosis , 2009, Nature.

[33]  P. Colman,et al.  BCL-2 family antagonists for cancer therapy , 2008, Nature Reviews Drug Discovery.

[34]  M. Berger,et al.  Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. , 1993, Journal of immunology.

[35]  Dimitri Semizarov,et al.  Integrative Genomic Analysis of Small-Cell Lung Carcinoma Reveals Correlates of Sensitivity to Bcl-2 Antagonists and Uncovers Novel Chromosomal Gains , 2007, Molecular Cancer Research.

[36]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[37]  Andreas Villunger,et al.  Bmf: A Proapoptotic BH3-Only Protein Regulated by Interaction with the Myosin V Actin Motor Complex, Activated by Anoikis , 2001, Science.

[38]  Tomomi Gotoh,et al.  ER Stress Triggers Apoptosis by Activating BH3-Only Protein Bim , 2007, Cell.

[39]  J. Díaz,et al.  Dimerization Properties of Human BAD , 1997, The Journal of Biological Chemistry.

[40]  P. Bouillet,et al.  Bim is a suppressor of Myc-induced mouse B cell leukemia. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  D. Andrews,et al.  Mechanisms of action of Bcl-2 family proteins. , 2013, Cold Spring Harbor perspectives in biology.

[42]  C. Tse,et al.  Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax) , 2015, Cell Death and Disease.

[43]  K. Roth,et al.  Mcl-1 deficiency results in peri-implantation embryonic lethality. , 2000, Genes & development.

[44]  C. Thompson,et al.  Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. , 1995, Cancer research.

[45]  D. Green,et al.  The Release of Cytochrome c from Mitochondria: A Primary Site for Bcl-2 Regulation of Apoptosis , 1997, Science.

[46]  Hao Xiong,et al.  Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  H. Puthalakath,et al.  BH3‐only proteins: a 20‐year stock‐take , 2015, The FEBS journal.

[48]  M. Peter,et al.  Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.

[49]  J. Sklar,et al.  Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[50]  R. Advani,et al.  Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies , 2015, British journal of haematology.

[51]  Keisuke Kuida,et al.  Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome , 2002, Nature.

[52]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[53]  Y. Shinomura,et al.  Over‐expression of bcl‐xL gene in human gastric adenomas and carcinomas , 1996, International journal of cancer.

[54]  S. Akira,et al.  Integral role of Noxa in p53-mediated apoptotic response. , 2003, Genes & development.

[55]  D. Andrews,et al.  Shedding Light on Apoptosis at Subcellular Membranes , 2012, Cell.

[56]  S. Korsmeyer,et al.  Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. , 1998, Blood.

[57]  A. Letai,et al.  BH3 profiling identifies three distinct classes of apoptotic blocks to predict response to ABT-737 and conventional chemotherapeutic agents. , 2007, Cancer cell.

[58]  K. Franssila,et al.  BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. , 1997, Blood.

[59]  C. Thompson,et al.  bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death , 1993, Cell.

[60]  T. McDonnell,et al.  Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14;18) , 1991, Nature.

[61]  G. Evan,et al.  Cooperative interaction between c-myc and bcl-2 proto-oncogenes , 1992, Nature.

[62]  H. Tagawa,et al.  Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM , 2005, Oncogene.

[63]  Y. Tsujimoto.  Stress-resistance conferred by high level of bcl-2 alpha protein in human B lymphoblastoid cell. , 1989, Oncogene.

[64]  J C Reed,et al.  Antisense-mediated inhibition of BCL2 protooncogene expression and leukemic cell growth and survival: comparisons of phosphodiester and phosphorothioate oligodeoxynucleotides. , 1990, Cancer research.

[65]  C. Milliman,et al.  BID: a novel BH3 domain-only death agonist. , 1996, Genes & development.

[66]  Erinna F. Lee,et al.  Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53 , 2014, Genes & development.

[67]  P. Nowell,et al.  Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. , 1984, Science.

[68]  M. Ichihashi,et al.  Accelerated disappearance of melanocytes in bcl-2-deficient mice. , 1996, Cancer research.

[69]  S. Korsmeyer,et al.  Bad, a heterodimeric partner for Bcl-xL and Bcl-2, displaces bax and promotes cell death , 1995, Cell.

[70]  Y. Hsu,et al.  Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[71]  N. Tjandra,et al.  BAX Activation is Initiated at a Novel Interaction Site , 2008, Nature.

[72]  A. Strasser,et al.  Antagonism between MCL-1 and PUMA governs stem/progenitor cell survival during hematopoietic recovery from stress. , 2015, Blood.

[73]  R. Meadows,et al.  X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death , 1996, Nature.

[74]  A. Strasser,et al.  Bcl‐2 and Fas/APO‐1 regulate distinct pathways to lymphocyte apoptosis. , 1995, The EMBO journal.

[75]  A. Strasser,et al.  Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2 , 1990, Nature.

[76]  K. J. Henley,et al.  Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease , 2013, Proceedings of the National Academy of Sciences.

[77]  A. Burgess,et al.  Malignant transformation of a growth factor-dependent myeloid cell line by Abelson virus without evidence of an autocrine mechanism , 1985, Cell.

[78]  M. Dyer,et al.  Ultrastructural localization of bcl-2 protein. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[79]  D. Green,et al.  Apoptotic cell death induced by c-myc is inhibited by bcl-2 , 1992, Nature.

[80]  Brian J. Smith,et al.  Structure-guided design of a selective BCL-X(L) inhibitor. , 2013, Nature chemical biology.

[81]  J C Reed,et al.  Somatic Frameshift Mutations in the BAX Gene in Colon Cancers of the Microsatellite Mutator Phenotype , 1997, Science.

[82]  S. Korsmeyer,et al.  Obligate Role of Anti-Apoptotic MCL-1 in the Survival of Hematopoietic Stem Cells , 2005, Science.

[83]  R. Santella,et al.  G3139 (oblimersen) may inhibit prostate cancer cell growth in a partially bis-CpG-dependent non-antisense manner. , 2003, Molecular cancer therapeutics.

[84]  H. Horvitz,et al.  Genetic control of programmed cell death in the nematode C. elegans , 1986, Cell.

[85]  S. Ming,et al.  Prognostic significance of Bcl-xL gene expression in human colorectal cancer. , 2011, Acta histochemica.

[86]  Robert A. Weinberg,et al.  Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes , 1983, Nature.

[87]  J. Rowley,et al.  Chromosome 14 translocations in non‐burkitt lymphomas , 1978, International journal of cancer.

[88]  W. Zong,et al.  Deficiency in Bak and Bax perturbs thymic selection and lymphoid homeostasis , 2002, Nature Immunology.

[89]  L. Lam,et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets , 2013, Nature Medicine.

[90]  Xiaodong Wang,et al.  Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c , 1996, Cell.

[91]  I. Weissman,et al.  Bcl-2 prevents death of factor-deprived cells but fails to prevent apoptosis in targets of cell mediated killing. , 1992, International immunology.

[92]  Nico Tjandra,et al.  Structure of Bax Coregulation of Dimer Formation and Intracellular Localization , 2000, Cell.

[93]  H. Varmus.  The molecular genetics of cellular oncogenes. , 1984, Annual review of genetics.

[94]  H. Feilotter,et al.  miR-193b Regulates Mcl-1 in Melanoma. , 2011, The American journal of pathology.

[95]  J. Opferman,et al.  NIX is required for programmed mitochondrial clearance during reticulocyte maturation , 2007, Proceedings of the National Academy of Sciences.

[96]  S. Korsmeyer,et al.  Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death , 2001, Science.

[97]  Erinna F. Lee,et al.  Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak , 2007, Science.

[98]  John Calvin Reed,et al.  Bcl-2 blocks apoptosis in cells lacking mitochondrial DNA , 1993, Nature.

[99]  M. Cleary,et al.  The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation , 1989, Molecular and cellular biology.

[100]  J. Sklar,et al.  Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation , 1986, Cell.

[101]  M. Konopleva,et al.  Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax). , 2008, Cancer research.

[102]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[103]  A. Letai,et al.  Pretreatment Mitochondrial Priming Correlates with Clinical Response to Cytotoxic Chemotherapy , 2011, Science.

[104]  S. Korsmeyer,et al.  Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. , 1990, Journal of immunology.

[105]  Matthew E. Ritchie,et al.  Sensitization of BCL-2–expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737 , 2011, Proceedings of the National Academy of Sciences.

[106]  A. Strasser,et al.  MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice. , 2014, Blood.

[107]  N. Inohara,et al.  harakiri, a novel regulator of cell death, encodes a protein that activates apoptosis and interacts selectively with survival‐promoting proteins Bcl‐2 and Bcl‐XL , 1997, The EMBO journal.

[108]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[109]  C. Tse,et al.  Activity of the Bcl-2 Family Inhibitor ABT-263 in a Panel of Small Cell Lung Cancer Xenograft Models , 2008, Clinical Cancer Research.

[110]  A. Strasser,et al.  Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. , 1999, Science.

[111]  J. Martinez-Climent,et al.  Reversion of epigenetically mediated BIM silencing overcomes chemoresistance in Burkitt lymphoma. , 2010, Blood.

[112]  Suzanne Cory,et al.  bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship , 1991, Cell.

[113]  S. Korsmeyer,et al.  Growth- and tumor-promoting effects of deregulated BCL2 in human B-lymphoblastoid cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[114]  M. Clarke,et al.  Bcl-XL protects cancer cells from p53-mediated apoptosis. , 1995, Oncogene.

[115]  J. Ihle,et al.  The v-fms oncogene induces factor-independent growth and transformation of the interleukin-3-dependent myeloid cell line FDC-P1. , 1987, Molecular and cellular biology.

[116]  al. et,et al.  Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice , 1995, Science.

[117]  W. Wilson,et al.  Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. , 2010, The Lancet. Oncology.

[118]  C. Tse,et al.  Bcl-2 family proteins are essential for platelet survival , 2007, Cell Death and Differentiation.

[119]  Matthew E. Ritchie,et al.  Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. , 2013, Cancer cell.

[120]  M. Nöthen,et al.  A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer , 2012, Nature Medicine.

[121]  Junying Yuan,et al.  Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.

[122]  S. Korsmeyer,et al.  Bax-Deficient Mice with Lymphoid Hyperplasia and Male Germ Cell Death , 1995, Science.

[123]  Mark A Sussman,et al.  Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure. , 2013, Genes & development.

[124]  S. Korsmeyer,et al.  Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis , 1999, Nature.

[125]  J. Sulston,et al.  Post-embryonic cell lineages of the nematode, Caenorhabditis elegans. , 1977, Developmental biology.

[126]  A. Strasser,et al.  BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice , 2012, Cell Death and Differentiation.

[127]  David S. Park,et al.  Mcl-1 Is a Key Regulator of Apoptosis during CNS Development and after DNA Damage , 2008, The Journal of Neuroscience.

[128]  Erinna F. Lee,et al.  Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis , 2013, Cell.

[129]  D. Vaux,et al.  Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[130]  S. Cory,et al.  ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. , 2013, Blood.

[131]  J. Opferman,et al.  Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia. , 2013, Blood.

[132]  P. Nowell,et al.  Oncogenic potential of bcl-2 demonstrated by gene transfer , 1988, Nature.

[133]  J. Martinou,et al.  Cloning of a bcl-2 homologue by interaction with adenovirus E1B 19K , 1995, Nature.

[134]  A. Hsueh,et al.  Bok is a pro-apoptotic Bcl-2 protein with restricted expression in reproductive tissues and heterodimerizes with selective anti-apoptotic Bcl-2 family members. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[135]  A. Strasser,et al.  BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes , 2002, Nature.

[136]  P. Ekert,et al.  Programmed Anuclear Cell Death Delimits Platelet Life Span , 2007, Cell.

[137]  A. Strasser,et al.  Degenerative disorders caused by Bcl-2 deficiency prevented by loss of its BH3-only antagonist Bim. , 2001, Developmental cell.

[138]  Richard W. Kriwacki,et al.  Many players in BCL-2 family affairs. , 2014, Trends in biochemical sciences.

[139]  T. Kipps,et al.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia. , 2016, The New England journal of medicine.

[140]  A. Strasser,et al.  The BCL-2 protein family, BH3-mimetics and cancer therapy , 2015, Cell Death and Differentiation.

[141]  G. Dewson,et al.  Mechanisms by which Bak and Bax permeabilise mitochondria during apoptosis , 2009, Journal of Cell Science.

[142]  S. Korsmeyer,et al.  Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1 , 2003, Nature.

[143]  David W. Andrews,et al.  Embedded together: The life and death consequences of interaction of the Bcl-2 family with membranes , 2007, Apoptosis.

[144]  S. Korsmeyer,et al.  Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair , 1993, Cell.

[145]  A. Letai,et al.  Targeting the B-cell lymphoma/leukemia 2 family in cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[146]  Andreas Villunger,et al.  p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa , 2003, Science.

[147]  C. Croce,et al.  miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[148]  G M Cohen,et al.  Different forms of cell death induced by putative BCL2 inhibitors , 2009, Cell Death and Differentiation.

[149]  A. Letai,et al.  Relative Mitochondrial Priming of Myeloblasts and Normal HSCs Determines Chemotherapeutic Success in AML , 2012, Cell.

[150]  D. Newmeyer,et al.  Cell-free apoptosis in Xenopus egg extracts: Inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria , 1994, Cell.

[151]  W. Zong,et al.  Gossypol induces Bax/Bak‐independent activation of apoptosis and cytochrome c release via a conformational change in Bcl‐2 , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[152]  W. Zong,et al.  BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. , 2001, Genes & development.

[153]  Samir Guglani.  Death , 1890, The Lancet.

[154]  S. Korsmeyer,et al.  Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around Jh on chromosome 14 and near a transcriptional unit on 18 , 1985, Cell.

[155]  S. Chen,et al.  Diva, a Bcl-2 Homologue that Binds Directly to Apaf-1 and Induces BH3-independent Cell Death* , 1998, The Journal of Biological Chemistry.

[156]  S. Korsmeyer,et al.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programed cell death , 1993, Cell.

[157]  C. Castilla,et al.  Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. , 2006, Endocrinology.

[158]  W. Pao,et al.  Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas , 2007, PLoS medicine.

[159]  M. Hinds,et al.  Structural biology of the Bcl-2 family and its mimicry by viral proteins , 2013, Cell Death and Disease.

[160]  A. Strasser,et al.  Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction , 2006, The Journal of experimental medicine.

[161]  Peter E. Czabotar,et al.  Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy , 2013, Nature Reviews Molecular Cell Biology.

[162]  A. Strasser,et al.  Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics , 2009, Nature Reviews Cancer.

[163]  A. Strasser,et al.  Bim: a novel member of the Bcl‐2 family that promotes apoptosis , 1998, The EMBO journal.

[164]  S. Korsmeyer,et al.  bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes , 1991, Cell.

[165]  T. Ley,et al.  Mcl 1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia , 2010 .

[166]  R. Schreiber,et al.  Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death , 1990, Nature.

[167]  David L. Vaux,et al.  Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells , 1988, Nature.

[168]  A. Wyllie,et al.  Apoptosis: A Basic Biological Phenomenon with Wide-ranging Implications in Tissue Kinetics , 1972, British Journal of Cancer.

[169]  Erinna F. Lee,et al.  Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. , 2012, Genes & development.

[170]  J. Cleveland,et al.  Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. , 1991, Oncogene.

[171]  S. Korsmeyer,et al.  bcl-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation , 1989, Cell.

[172]  R. Hotchkiss,et al.  Cell death. , 2009, The New England journal of medicine.

[173]  Jiawei Han,et al.  Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[174]  P. Marrack,et al.  The structure of a Bcl-xL/Bim fragment complex: implications for Bim function. , 2003, Immunity.

[175]  Stefan P. Glaser,et al.  Mcl-1 Is Essential for Germinal Center Formation and B Cell Memory , 2010, Science.

[176]  A. Strasser,et al.  E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. , 1993, Oncogene.

[177]  Matthew J. Brauer,et al.  Modulation of apoptosis by the widely distributed Bcl-2 homologue Bak , 1995, Nature.

[178]  A. Strasser,et al.  In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute , 2008, Cell Death and Differentiation.

[179]  Brian J. Smith,et al.  Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. , 2005, Molecular cell.

[180]  Shai Shaham,et al.  The C. elegans cell death gene ced-3 encodes a protein similar to mammalian interleukin-1β-converting enzyme , 1993, Cell.

[181]  S. Korsmeyer,et al.  The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. , 2000, Molecular cell.

[182]  T. Ley,et al.  Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. , 2009, The Journal of clinical investigation.

[183]  Saul H. Rosenberg,et al.  The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo , 2010, Cancer Chemotherapy and Pharmacology.

[184]  A. Strasser,et al.  Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. , 2010, Blood.

[185]  Atsushi Hase,et al.  The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis , 1991, Cell.

[186]  Y. Doki,et al.  The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma. , 2010, Journal of hepatology.

[187]  V. Stewart,et al.  Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. , 1993, Science.

[188]  J. Cleveland,et al.  Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. , 2003, Cancer cell.

[189]  H. Horvitz,et al.  C. elegans cell survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2 , 1994, Cell.

[190]  T. Jacks,et al.  DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2 , 1994, Cell.

[191]  N. Copeland,et al.  bcl-w, a novel member of the bcl-2 family, promotes cell survival. , 1996, Oncogene.

[192]  Stefan P. Glaser,et al.  Mcl-1 is essential for the survival of plasma cells , 2013, Nature Immunology.

[193]  Y. Tsujimoto,et al.  Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[194]  D. Vaux,et al.  Apaf-1 and caspase-9 accelerate apoptosis, but do not determine whether factor-deprived or drug-treated cells die , 2004, The Journal of cell biology.

[195]  D. Vaux,et al.  Abnormalities of the immune system induced by dysregulated bcl-2 expression in transgenic mice. , 1990, Current topics in microbiology and immunology.

[196]  A. Strasser,et al.  BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. , 2005, Blood.

[197]  M. Amiot,et al.  ABT-737 Induces Apoptosis in Mantle Cell Lymphoma Cells with a Bcl-2high/Mcl-1low Profile and Synergizes with Other Antineoplastic Agents , 2011, Clinical Cancer Research.